Hammarstrand C, et al. - In patients with non-functioning pituitary adenomas (NFPA) with and without growth hormone replacement therapy (GHRT), researchers examined comorbidities, including cerebral infarction, type 2 diabetes mellitus (T2DM) and malignant tumors. Participants in the study were 426 patients with NFPA within the western region of Sweden. The results of this observational cohort study indicate that the incidence of cerebral infarction was increased in patients with NFPA irrespective of GHRT. Findings revealed that despite having a higher body mass index (BMI), patients without GHRT had an increased risk of T2DM, while patients with GHRT had a normal incidence of T2DM. They did not find an increase in the incidence of malignant tumors. Outcomes suggested that long-term GHRT appears to be safe in terms of the risk of comorbidities.